2023
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial
Ross J, Perumal R, Wolf A, Zulu M, Guzman K, Seepamore B, Reis K, Nyilana H, Hlathi S, Narasimmulu R, Cheung Y, Amico K, Friedland G, Daftary A, Zelnick J, Naidoo K, O’Donnell M. Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial. Trials 2023, 24: 776. PMID: 38037105, PMCID: PMC10691086, DOI: 10.1186/s13063-023-07520-9.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisAdherence support interventionsAntiretroviral therapyTreatment regimensAdherence supportPrimary outcomeTreatment supportPsychosocial supportMDR-TB treatment regimensUndetectable HIV viral loadSupport interventionsIntegrase strand transfer inhibitorsAdherence support strategiesComposite clinical outcomeMDR-TB regimensNegative TB culturesCombination antiretroviral therapyComposite primary outcomeHIV treatment outcomesHIV viral loadDrug-resistant tuberculosisStandard of careNew treatment regimensDifferentiated service deliveryStrand transfer inhibitorsBuilding an Infectious Disease Diversity, Equity, and Antiracism (ID2EA) Curriculum: A Single Center's Experience and Reflections
Gleeson S, Zapata H, Bathgate M, Emu B, Frederick J, Friedland G, Golden M, Meyer J, Radin J, Sideleau R, Shaw A, Shenoi S, Trubin P, Virata M, Barakat L, Desruisseaux M. Building an Infectious Disease Diversity, Equity, and Antiracism (ID2EA) Curriculum: A Single Center's Experience and Reflections. Clinical Infectious Diseases 2023, 77: 703-710. PMID: 37078888, DOI: 10.1093/cid/ciad236.Peer-Reviewed Original ResearchConceptsEducational activitiesHealthcare inequitiesInfectious Diseases SectionSingle-center experienceCoronavirus disease 2019 (COVID-19) pandemicDisease 2019 pandemicMixed-methods assessmentLearning objectivesPilot curriculumEducational trainingCurriculumCenter experienceLong-term behavioral changesProgram outcomesDisease sectionDisease diversityPhysician perspectivesResponse rateHealth disparitiesYale SchoolInequitiesAntiracismBehavioral changesRacismEquity
2022
Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)
Tuan JJ, Zapata H, Barakat L, Andrews L, Behnegar A, Kim YW, Kayani J, Mutic S, Ryall L, Turcotte B, Critch-Gilfillan T, Zhao M, Salahuddin S, Gupta S, Sutton R, Friedland G, Emu B, Ogbuagu O. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH). BMC Infectious Diseases 2022, 22: 744. PMID: 36131232, PMCID: PMC9491266, DOI: 10.1186/s12879-022-07737-0.Peer-Reviewed Original ResearchConceptsT cell responsesAnti-spike IgGVisit 3SARS-CoV-2Older PWHVisit 2Immune responseSingle-center longitudinal observational studyVirus-specific T cell responsesVaccine-induced humoral immunityLong-term protective immunityT cell immune responsesOlder peopleMedian age 61RBD IgG levelsPrimary study outcomeCOVID-19 vaccinationImmune response evaluationLongitudinal observational studyCOVID-19 vaccineWilcoxon signed-rank testBNT162b2 boosterBNT162b2 vaccinationCD8 responsesDetectable CD4Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS
O'Donnell MR, Padayatchi N, Wolf A, Zelnick J, Daftary A, Orrell C, Nimmo C, Baldwin M, Boodhram R, Maharaj B, Amico KR, Naidoo K, Friedland G. Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2022, 90: 325-332. PMID: 35195572, PMCID: PMC11077859, DOI: 10.1097/qai.0000000000002940.Peer-Reviewed Original ResearchConceptsMDR-TB treatment outcomesResistance-associated variantsTreatment outcomesAntiretroviral therapyMDR-TBART adherenceMultidrug-resistant tuberculosis treatmentHIV treatment outcomesProspective cohort studyMultidrug-resistant tuberculosisEnd of treatmentTreatment of patientsSuccessful treatment outcomeElectronic dose monitoring devicesHIV/AIDSCohort studyClinical outcomesMultivariable analysisNovel regimensMedication adherenceAdherence thresholdTuberculosis treatmentTreatment completionLow adherenceDose monitoringAdherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis
Bateman M, Wolf A, Chimukangara B, Brust JCM, Lessells R, Amico R, Boodhram R, Singh N, Orrell C, Friedland G, Naidoo K, Padayatchi N, O’Donnell MR. Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases 2022, 75: 1489-1496. PMID: 35352097, PMCID: PMC9617578, DOI: 10.1093/cid/ciac232.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisHuman immunodeficiency virusMDR-TB treatmentART adherenceART resistanceHuman immunodeficiency virus/AIDSEmergent resistanceStandard of careResource-limited settingsTB regimensAntiretroviral resistanceHIV RNAProspective cohortMedication adherenceImmunodeficiency virusPoor outcomeShort followAdherence thresholdCopies/Treatment outcomesDose monitoringResistance mutationsResistance testingPublic hospitalsLinear associationManaging COVID-19 going forward—the lessons from history
Bucala R, Friedland G, Snowden F. Managing COVID-19 going forward—the lessons from history. QJM 2022, 115: 649-650. PMID: 35262710, PMCID: PMC9383561, DOI: 10.1093/qjmed/hcac065.Peer-Reviewed Original ResearchExperiences with Telemedicine for HIV Care During the COVID-19 Pandemic: A Mixed-Methods Study
Harsono D, Deng Y, Chung S, Barakat LA, Friedland G, Meyer JP, Porter E, Villanueva M, Wolf MS, Yager JE, Edelman EJ. Experiences with Telemedicine for HIV Care During the COVID-19 Pandemic: A Mixed-Methods Study. AIDS And Behavior 2022, 26: 2099-2111. PMID: 35064390, PMCID: PMC8782707, DOI: 10.1007/s10461-021-03556-7.Peer-Reviewed Original ResearchConceptsHIV careRe-engage patientsMixed-methods studyCare team membersRoutine clinical experienceCOVID-19 pandemicBenefits of telemedicineHIV clinicTelemedicine visitsTelemedicine appointmentsReimbursement concernsClinical experienceClinical staffCareAppropriate billingPatientsPWHTelemedicinePatient remote monitoringReimbursement methodsPandemicHIVClinicVisits
2020
TB and women: a call to action
Daftary A, Furin J, Zelnick J, Venkatesan N, Steingart K, Smelyanskaya M, Seepamore B, Schoeman I, Reid M, Padayatchi N, O Donnell M, Mistry N, McKenna L, Mahbub T, Macdonald H, Loveday M, Law S, LaCourse S, Jaramillo E, Janssen R, Hirsch-Moverman Y, Friedland G, Creswell J, Chorna Y, Chikovore J, Brigden G, Boffa J, Boehme C, Atre S, Amico K, Acquah R, Engel N. TB and women: a call to action. The International Journal Of Tuberculosis And Lung Disease 2020, 24: 1312-1315. PMID: 33317679, DOI: 10.5588/ijtld.20.0414.Peer-Reviewed Original ResearchPreventing COVID-19 Collateral Damage
Shepherd J, Friedland G. Preventing COVID-19 Collateral Damage. Clinical Infectious Diseases 2020, 71: 1564-1567. PMID: 32544952, PMCID: PMC7337641, DOI: 10.1093/cid/ciaa772.Peer-Reviewed Original ResearchConfronting Another Pandemic: Lessons from HIV can Inform Our COVID-19 Response
Edelman EJ, Aoun-Barakat L, Villanueva M, Friedland G. Confronting Another Pandemic: Lessons from HIV can Inform Our COVID-19 Response. AIDS And Behavior 2020, 24: 1977-1979. PMID: 32399798, PMCID: PMC7215127, DOI: 10.1007/s10461-020-02908-z.Peer-Reviewed Original Research
2019
Opportunities for community health workers to contribute to global efforts to end tuberculosis
Sinha P, Shenoi SV, Friedland GH. Opportunities for community health workers to contribute to global efforts to end tuberculosis. Global Public Health 2019, 15: 474-484. PMID: 31516079, PMCID: PMC7028491, DOI: 10.1080/17441692.2019.1663361.Peer-Reviewed Original ResearchImpact of early antiretroviral treatment on sexual behaviour: a randomised comparison
Lampe FC, Rodger AJ, Burman W, Grulich A, Friedland G, Sadr WE, Neaton J, Corbelli GM, Emery S, Molina JM, Orkin C, Gatell J, Gerstoft J, Ruxrungtham K, de Souza M, Phillips AN. Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison. AIDS 2019, 33: 2337-2350. PMID: 31764099, PMCID: PMC6882545, DOI: 10.1097/qad.0000000000002359.Peer-Reviewed Original ResearchConceptsEarly antiretroviral treatmentHIV-serodifferent partnersAntiretroviral treatmentMonth 12Month 24CD4 cell countHIV-positive adultsSexual behaviorHIV infectiousnessImmediate armViral suppressionPrimary outcomeHigh prevalenceCondomless sexCell countMSMCells/Lower absolute levelsSexHeterosexual menTreatmentHeterosexualsArmAbsolute levelsPrevalenceAntiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection
O'Donnell MR, Padayatchi N, Daftary A, Orrell C, Dooley KE, Amico K, Friedland G. Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection. The Lancet HIV 2019, 6: e201-e204. PMID: 30846058, PMCID: PMC7155388, DOI: 10.1016/s2352-3018(19)30035-9.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisBedaquiline treatmentTuberculosis-HIVLow antiretroviral therapy adherencePotent new therapyAntiretroviral therapy initiationAntiretroviral therapy adherenceEfavirenz-containing regimensFixed-dose combinationAntiretroviral therapy switchMiddle-income settingsDaily nevirapineAdherence supportAntiretroviral resistanceAntiretroviral therapyHIV patientsTherapy initiationViral failureTherapy switchImproved survivalTherapy adherenceDrug interactionsNew therapiesHIVBedaquiline
2018
Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa
Bionghi N, Daftary A, Maharaj B, Msibi Z, Amico K, Friedland G, Orrell C, Padayatchi N, O’Donnell M. Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa. BMC Infectious Diseases 2018, 18: 171. PMID: 29642874, PMCID: PMC5896111, DOI: 10.1186/s12879-018-3080-2.Peer-Reviewed Original ResearchConceptsAnti-retroviral therapySeven-day recallPill countMedication adherenceWisepill deviceTreatment regimensTB/HIV co-infected patientsHIV co-infected adultsHIV co-infected patientsDrug-resistant tuberculosis treatmentCo-infected adultsCo-infected patientsDR-TB treatmentPilot study patientsWeekly pill countsComplex treatment regimensElectronic pill boxesLevel of adherenceTB regimensAdherence supportAntiretroviral therapyHIV patientsStudy patientsMethodsEligible patientsNew antimycobacterial drugs
2017
Turning the tide against tuberculosis
Padayatchi N, Naidu N, Friedland G, Naidoo K, Conradie F, Naidoo K, O’Donnell M. Turning the tide against tuberculosis. International Journal Of Infectious Diseases 2017, 56: 6-9. PMID: 28167256, DOI: 10.1016/j.ijid.2017.01.012.Peer-Reviewed Original Research
2016
Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa
Gilbert JA, Shenoi SV, Moll AP, Friedland GH, Paltiel AD, Galvani AP. Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa. PLOS ONE 2016, 11: e0165614. PMID: 27906986, PMCID: PMC5131994, DOI: 10.1371/journal.pone.0165614.Peer-Reviewed Original ResearchConceptsTB/HIVTB/HIV controlHIV screeningHIV controlRural South AfricaLife yearsMonths of IPTMost life yearsHigh-incidence settingsWidespread prevalenceCost-effectiveness resultsProbabilistic sensitivity analysesHIV transmissionHigh burdenTreatment coverageUnknown patientsHIVHealthcare accessDrug resistanceActive casesMonthsLifetime usePatientsYearsScreeningImpact of nurse-delivered community-based CD4 services on facilitating pre-ART care in rural South Africa
Kompala T, Moll AP, Mtungwa N, Brooks RP, Friedland GH, Shenoi SV. Impact of nurse-delivered community-based CD4 services on facilitating pre-ART care in rural South Africa. BMC Health Services Research 2016, 16: 374. PMID: 27515233, PMCID: PMC4982129, DOI: 10.1186/s12913-016-1627-8.Peer-Reviewed Original ResearchConceptsPre-ART careAntiretroviral treatmentCD4 testingCBVCT servicesTreatment cascadeRural South AfricaLocal primary care clinicsCD4 count resultsCommunity-based voluntary counselingPrimary care clinicsHIV-positive clientsPhlebotomy servicesResource-limited settingsART initiationHIV careART eligibilityCare cascadeCare clinicsHIV-positiveVoluntary counselingTreatment eligibilityCD4 resultsResult notificationResultsBetween 2010Nurse presenceMarking Time in the Global HIV/AIDS Pandemic
Friedland G. Marking Time in the Global HIV/AIDS Pandemic. JAMA 2016, 316: 145-146. PMID: 27404179, DOI: 10.1001/jama.2016.9006.Peer-Reviewed Original ResearchDrug interactions between buprenorphine, methadone and hepatitis C therapeutics
Ogbuagu O, Friedland G, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opinion On Drug Metabolism & Toxicology 2016, 12: 721-731. PMID: 27140427, DOI: 10.1080/17425255.2016.1183644.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDirect acting antiviralsOpioid use disorderDrug interactionsUse disordersHCV direct acting antiviralsNovel direct acting antiviralsHepatitis C virus infectionHepatitis C therapeuticsHigh HCV prevalenceC virus infectionMedication-assisted therapyPharmacodynamic drug interactionsSpecific drug combinationsDrug package insertsHCV prevalenceHCV infectionHCV treatmentOpioid withdrawalActing antiviralsCombination regimenPharmacodynamic assessmentConcurrent administrationDrug levelsHigh prevalenceVirus infectionRe-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV
O'Donnell MR, Daftary A, Frick M, Hirsch-Moverman Y, Amico KR, Senthilingam M, Wolf A, Metcalfe JZ, Isaakidis P, Davis JL, Zelnick JR, Brust JC, Naidu N, Garretson M, Bangsberg DR, Padayatchi N, Friedland G. Re-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV. The International Journal Of Tuberculosis And Lung Disease 2016, 20: 430-434. PMID: 26970149, PMCID: PMC4863995, DOI: 10.5588/ijtld.15.0360.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusDrug-resistant TBMedication adherenceNational TB Control ProgrammeDrug-resistant tuberculosisTB control programsPatient-centered modelPatient-centered careNew antimycobacterial agentsUnderstanding of adherenceHealth care systemAdherence supportTB-HIVObserved therapyImmunodeficiency virusComprehensive careTreatment outcomesTreatment supportTuberculosis diagnosticsPatientsCare systemCareAntimycobacterial agentsTreatment deliveryAdherence